n-acetyl-s-farnesylcysteine has been researched along with rosiglitazone in 1 studies
| Studies (n-acetyl-s-farnesylcysteine) | Trials (n-acetyl-s-farnesylcysteine) | Recent Studies (post-2010) (n-acetyl-s-farnesylcysteine) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 42 | 0 | 6 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | n-acetyl-s-farnesylcysteine (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhalla, K; Choi, JH; Dewi, R; Girnun, GD; Hwang, BJ; Mclenithan, J; Ou, L; Pozharski, E; Stock, J; Twaddel, W | 1 |
1 other study(ies) available for n-acetyl-s-farnesylcysteine and rosiglitazone
| Article | Year |
|---|---|
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Topics: 3T3-L1 Cells; Acetylcysteine; Animals; Cysteine; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2011 |